Session » Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

Date: Sunday, November 12, 2023

Time: 4:00PM-5:30PM

Meeting: ACR Convergence 2023

Abstract Number: 0823

Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort

Abstract Number: 0824

Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study

Abstract Number: 0825

A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)

Abstract Number: 0826

Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus

Abstract Number: 0827

Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease

Abstract Number: 0828

Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.